Phase 2 Interstitial Lung Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with active pulmonary sarcoidosis (sarcoidosis affecting the lungs) that is causing symptoms, confirmed according to established medical guidelines.
• People who are either new to treatment for sarcoidosis or have been treated for it before.
• People whose lung tissue shows signs of active disease on a special type of body scan called an [18F]FDG PET/CT scan.

Who may not be able to join:

• People who need to start standard sarcoidosis treatment immediately.
• People who have sarcoidosis that is currently affecting the heart or nervous system.
• People who have a history of, or currently have, a condition called Löfgren syndrome (a specific form of sarcoidosis).
• People who have a significant lung disease other than sarcoidosis — such as tuberculosis, asthma, chronic obstructive pulmonary disease (COPD), another type of scarring lung disease, or lung cancer — or who have any other ongoing inflammatory or immune system disease besides sarcoidosis.
• People who are currently taking, or have recently taken, certain medications for sarcoidosis: specifically, corticosteroids taken within the last 3 months, or immunosuppressants or anti-inflammatory/anti-fibrotic drugs taken within the last 4 months.
• People whose main reason for needing systemic treatment is sarcoidosis in a part of the body other than the lungs (for example, in the nervous system).
• People with certain heart conditions, including a specific abnormality on a heart tracing (prolonged QTcF interval), certain heart rhythm problems, moderate-to-severe heart failure, known thickening of the heart muscle, or reduced heart pumping function seen on a cardiac MRI.
• People with a known diagnosis of neurosarcoidosis (sarcoidosis affecting the nerves), a nerve condition called small fiber neuropathy, or any medical condition that causes problems with balance and coordination (primary ataxia).
• People with certain abnormal blood test results at the time of screening, including abnormal liver markers, abnormal kidney function, low potassium, low calcium, or significantly elevated fasting blood sugar levels.
• People with poorly controlled diabetes at the time of screening, a body temperature above 37°C, or any other condition that would make the PET/CT scan unsuitable or unsafe (confirm with trial site).
• People who test positive for HIV, hepatitis B, or hepatitis C, either previously known or detected at screening.
• People with a severe or poorly controlled serious illness — such as a heart, lung, thyroid, kidney, or metabolic condition — that the trial doctor believes could affect safety or the ability to participate.
• People who currently smoke more than 5 cigarettes or e-cigarettes per day, or regularly use other nicotine products such as patches or chewing gum.
• People currently taking certain medications, including drugs known to affect heart rhythm (QT-prolonging drugs), thiazide diuretics (a type of fluid tablet), certain drugs that affect how the body processes other medications (strong CYP3A4 inhibitors or inducers, P-glycoprotein or BCRP inhibitors, or specific drug transporters with a narrow margin of safety), or the lung-scarring medications pirfenidone or nintedanib.

Important: Always verify eligibility with the trial site directly before applying.